Recombinant IgA Oligomers for Robust IgAN Animal Models
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current animal models for IgA nephropathy are not robust enough for therapeutic drug screening due to unpredictable onset of glomerular deposits and lack of molecular characterization, particularly because they do not accurately replicate the human-specific O-glycosylation states of the IgA1 hinge region, making it challenging to understand and treat the disease effectively.
Innovation Solution
A recombinant IgA analog with a biotin tag is artificially induced to form high-order oligomers, which deposits in the glomerular mesangium of rats, mimicking IgA nephropathy pathology and allowing for the study of polymeric IgA deposition and clearance dynamics, thereby creating a more reliable animal model for drug screening and diagnostic evaluation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If spontaneous or induced models of IgA deposition are used in animals, then IgA deposits can be observed in the kidney, but the onset of glomerular deposits is unpredictable and the models lack robustness for therapeutic drug screening
Solution Approach 1:
The patent applies preliminary action by pre-characterizing the poly-IgA from patient biopsies before injection into animals. The poly-IgA is isolated, purified, and molecularly characterized (including O-glycosylation states) in advance, ensuring that when injected, it produces consistent and predictable IgA nephropathy models. This pre-preparation of the injectate resolves the unpredictability issue of spontaneous models.
Solution Approach 2:
The patent changes key parameters of the animal model by using specifically characterized poly-IgA with defined molecular properties (size, O-glycosylation state, isoelectric point) instead of crude IgA preparations. This parameter control ensures reproducible deposition patterns and disease progression, making the model reliable for therapeutic screening while maintaining predictable timing.
2Reliability
If poly-IgA extracted from IgAN patients is injected in large quantities to mice, then renal deposition can be caused, but variability in IgA donors and lack of molecular characterization make the models not robust enough
Solution Approach 1:
The patent replaces the variable biological system (different patient IgA donors) with a standardized molecular characterization system. Each poly-IgA preparation is analyzed for molecular weight distribution, O-glycosylation states, isoelectric point, and other physical-chemical parameters. This substitution of biological variability with measurable physical parameters ensures consistency across different batches and donors.
Solution Approach 2:
The patent creates a standardized copy of pathogenic poly-IgA by isolating and characterizing the specific molecular features from patient samples. The characterized poly-IgA serves as a reproducible template that can be injected into animals to generate consistent IgA nephropathy models, eliminating donor variability while preserving the pathogenic molecular characteristics.
3Adaptability or versatility
If animal models are used to study IgA nephropathy, then disease mechanisms can be investigated, but the absence of human-specific O-glycosylation states in experimental animals makes it challenging
Solution Approach 1:
The patent uses characterized poly-IgA as an intermediary that bridges the gap between human disease pathology and animal model systems. The poly-IgA retains human-specific O-glycosylation states and molecular characteristics, serving as a mediator that transfers the specific molecular features of human IgA nephropathy into the animal model, enabling study of human-specific mechanisms in non-human animals.
Solution Approach 2:
The patent applies local quality by preserving the specific human-specific O-glycosylation states and molecular characteristics of poly-IgA in the injected preparation, while the rest of the animal model system can be non-human. This localized preservation of human-specific molecular features in the critical pathogenic element (poly-IgA) enables accurate modeling of human disease mechanisms without requiring the entire animal to be human.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant IgA model induces renal and systemic responses, leading to prominent glomerular mesangial deposition and clearance, providing a reliable platform for evaluating therapeutic drugs and diagnostics for IgA nephropathy, and allowing for the study of disease progression and treatment efficacy.
Implementation Method 1
A method for producing an IgA nephropathy animal model includes providing a polymeric complex of unglycosylated IgA oligomeric fragments; and administering to an animal the polymeric complex of unglycosylated IgA fragments
Data Source
AI summary
Recombinant poly-IgA oligomers that form high-order oligomers resembling poly-IgA of IgA nephropathy are provided. Injection of recombinant IgA oligomers in an animal model produces prominent renal glomerular mesangial deposition of recombinant poly IgA oligomer, as in IgA nephropathy patients. Thus, producing a model of IgAN pathology that is able to provide screening and evaluation of therapeutic drugs and diagnostic tests.